07/22/14 - 09:41 AM EDT
Galena stands little chance of delivering higher sales of Zuplenz than its previous marketer.READ FULL POST
07/15/14 - 01:10 PM EDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.READ FULL POST
07/14/14 - 11:14 AM EDT
Healthcare investor David Miller believes Roche will likely acquire Exelixis in order to capture the full economics of the cancer drug cobimetinib.READ FULL POST
07/14/14 - 07:46 AM EDT
Roche intends to seek U.S. approval for cobimetinib later this year.READ FULL POST
07/08/14 - 09:52 AM EDT
The SEC halts trading in Radient Pharmaceuticals.READ FULL POST
07/08/14 - 09:14 AM EDT
Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.READ FULL POST
07/07/14 - 02:49 PM EDT
Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.READ FULL POST
07/07/14 - 11:23 AM EDT
Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.READ FULL POST
06/25/14 - 01:05 PM EDT
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.READ FULL POST
06/24/14 - 12:07 PM EDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.